First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Navigator: the story is balanced — BEKP benchmark pulp prices: Northern Europe list prices directly impact 35-40% of revenue with high flow-through…
What Moves the Stock
1BEKP benchmark pulp prices: Northern Europe list prices directly impact 35-40% of revenue with high flow-through to EBITDA
2European UWF paper demand and pricing: Office paper volumes declining 2-4% annually due to digitalization, pricing discipline critical
3EUR/USD exchange rate: ~60% of revenue export-driven, weaker euro improves competitiveness versus Nordic and North American producers
4Energy costs: Natural gas and electricity prices for the 35% non-biomass energy needs, particularly relevant post-2022 European energy crisis
5Chinese tissue and paper demand: Asia represents 25-30% of pulp sales, sensitive to Chinese construction and consumer activity
6Uncoated woodfree paper (~50-55% of revenue): Premium office paper, copy paper sold to European distributors and converters
7Pulp (~35-40% of revenue): BEKP sold to tissue manufacturers and specialty paper producers globally, particularly Asia
8Tissue paper and other products (~10-15% of revenue): Consumer tissue brands and specialty papers
value - The stock trades at 1.7x book value and 7.9x EV/EBITDA with 11.9% ROE…
Rising rates increase financing costs on the company's €600-800 million net debt position (D/E 0.71)…
Watch on earnings: NBSK/BEKP pulp price indices (PIX Pulp benchmark for Europe), European UWF paper price indices and shipment data from CEPI (Confederation of European Paper Industries), EUR/USD exchange rate and EUR/CNY for Asian export competitiveness.
One Sentence Summary:
Navigator: the story is balanced — bekp benchmark pulp prices: northern europe list prices directly impact 35-40% of revenue with high flow-through to ebitda.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.